A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

NCT00500903 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Millennium Pharmaceuticals, Inc.